How do pediatric dermatology nurses explain why tacrolimus ointment is used instead of hydrocortisone on the face and flexural areas to Spanish-speaking parents?

The tacrolimus versus topical corticosteroid conversation is one of the most common communication challenges in pediatric dermatology, because parents have usually had a direct experience of topical steroids working — the child's skin improved, the itch decreased, the redness faded — and they cannot understand why a treatment that worked is being replaced rather than continued. The nurse must explain two things: what tacrolimus does mechanistically and how it differs from corticosteroids, and why the face and flexural areas are anatomically different from other skin sites in ways that make prolonged topical steroid use harmful there even when short-term benefit is clear. Hydrocortisone and other topical corticosteroids work through glucocorticoid receptor activation. When the steroid molecule penetrates the epidermis and dermis, it binds to intracellular glucocorticoid receptors in keratinocytes, fibroblasts, endothelial cells, and resident immune cells. The activated glucocorticoid receptor acts as a transcription factor that suppresses the production of pro-inflammatory cytokines — IL-1β, TNF-α, IL-6, IL-4, IL-13, TSLP — reduces arachidonic acid metabolism and prostaglandin synthesis, and impairs antigen-presenting cell function. The result is rapid, broad suppression of the inflammatory milieu in the treated skin. The skin looks and feels better because the inflammation is chemically suppressed. But glucocorticoid receptor activation also affects non-immune cells in the dermis. Fibroblasts under chronic glucocorticoid signaling reduce collagen and elastin synthesis and reduce their own proliferation. The dermis becomes thinner. The microscopic structural scaffold that supports the epidermis loses tensile strength. Dermal vessels — which depend on the structural support of the surrounding dermis — dilate and become more fragile, producing the fine red vessels (telangiectasia) visible on chronically steroid-treated skin. In children, who have thinner skin with higher surface-area-to-body-weight ratios and a higher rate of systemic absorption through skin than adults, prolonged application of topical steroids — even mild-potency preparations like hydrocortisone 1% — to large areas of inflamed skin can produce measurable systemic cortisol suppression and hypothalamic-pituitary-adrenal axis blunting. The face is anatomically the most vulnerable site because the facial skin is the thinnest in the body, with a large number of sebaceous follicles that enhance percutaneous absorption, and because visible cosmetic adverse effects — atrophy, telangiectasia, perioral dermatitis, steroid rosacea — are most clinically apparent and distressing on the face. The antecubital and popliteal fossae — the inner elbow and back of the knee, the two most common sites of childhood atopic dermatitis — are flexural areas where skin-to-skin occlusion enhances steroid absorption above what the baseline percutaneous rate predicts. Tacrolimus works through a completely different mechanism that does not involve glucocorticoid receptors and does not affect fibroblast function, collagen synthesis, or vessel wall integrity. Tacrolimus binds intracellular FKBP12 (FK506-binding protein 12), and the tacrolimus-FKBP12 complex inhibits calcineurin — the phosphatase enzyme that dephosphorylates NFAT (nuclear factor of activated T cells). When calcineurin is blocked, NFAT remains phosphorylated and cannot translocate to the T-cell nucleus. Without NFAT nuclear translocation, the T cell cannot transcribe IL-2 — the autocrine growth and activation signal that drives T-cell proliferation and effector function. Without adequate IL-2 signaling, the T cells in the dermis and epidermis that are driving the atopic inflammation cannot sustain their activation. The inflammation resolves at the immune effector cell level, not through the broad transcriptional suppression that corticosteroids produce. Because tacrolimus does not engage glucocorticoid receptors, it does not suppress fibroblast function, does not thin the dermis, does not impair collagen synthesis, and does not produce skin atrophy or telangiectasia — regardless of how long or how frequently it is applied. This is the mechanistic reason it is the preferred treatment for the face and flexural areas in children with atopic dermatitis: it is as effective as medium-potency topical corticosteroids for controlling atopic inflammation, with a safety profile that does not worsen with anatomical site or duration of use. For the Spanish-speaking parent, the nurse should frame it this way: 'La hidrocortisona funciona suprimiendo la inflamación con mucha potencia — eso es exactamente por qué funciona. Pero esa supresión también afecta a las células que mantienen la piel firme y gruesa. En la cara y los pliegues, donde la piel ya es naturalmente más delgada y absorbe más el medicamento, usar hidrocortisona por mucho tiempo puede adelgazar la piel y afectar los vasos pequeños. Tacrolimus no es un esteroide — funciona de una manera completamente diferente, bloqueando solo las células inmunes que causan la inflamación, sin afectar las células que mantienen la estructura de la piel. El resultado visible puede ser muy parecido — la piel mejora, el picor baja — pero sin los efectos secundarios que los esteroides producen con el uso prolongado en la cara.'

How do pediatric dermatology nurses explain dupilumab to Spanish-speaking parents when topical treatments for severe atopic dermatitis have failed?

The dupilumab conversation when topical treatments have been maximized is one of the most important communication moments in pediatric dermatology, because the family has typically been through months or years of topical treatment with partial benefit and is now being asked to accept subcutaneous injections for a skin condition — an escalation that many families interpret as the disease being worse than they realized rather than as a treatment being more targeted and effective. The nurse must explain what topical treatments can and cannot do, what dupilumab does and why it works where topicals cannot, and why the injection route is necessary for this mechanism. Topical treatments for atopic dermatitis — corticosteroids, calcineurin inhibitors like tacrolimus and pimecrolimus, and phosphodiesterase-4 inhibitors like crisaborole — all work at the level of the skin itself. When applied to the inflamed epidermis and dermis, they suppress the local inflammatory milieu: reducing cytokine production in activated keratinocytes and T cells at the treatment site, reducing eosinophil accumulation, and reducing the itch and erythema that result from this inflammation. They are effective for controlling atopic dermatitis where it is applied, with the limitations of the application site. But atopic dermatitis is not only a skin disease — it is a systemic Th2 immune dysregulation that manifests primarily in the skin. The underlying driver is an overactivated Th2 immune axis: Th2-polarized CD4+ T cells in the blood and lymphoid tissue produce excessive quantities of IL-4 and IL-13. These cytokines circulate systemically and reach the skin, where they act on keratinocytes through IL-4Rα/IL-13Rα1 receptor complexes. IL-4 and IL-13 signaling in keratinocytes downregulates the production of structural proteins essential for the skin barrier — filaggrin (which aggregates keratin filaments in the stratum corneum and contributes to natural moisturizing factor), loricrin (a component of the cornified envelope), and involucrin (another cornified envelope protein). When filaggrin production is reduced, the stratum corneum develops microstructural gaps that allow external irritants and allergens to penetrate, triggering further immune activation and perpetuating the inflammation cycle. IL-4 also drives IgE class switching in B cells — it is the primary cytokine that instructs B cells to switch their antibody production from IgM to IgE — contributing to the elevated total IgE and allergen-specific IgE that characterizes atopic dermatitis. IL-13 drives the goblet cell metaplasia and mucus hypersecretion that manifests as the comorbid asthma and allergic rhinitis seen in many children with severe atopic dermatitis. IL-31, produced by the Th2-activated cells in the skin, signals through IL-31Rα on sensory neurons to produce the intense, chronic itch that is the defining symptom of severe atopic dermatitis and one of the primary causes of sleep disruption, behavioral problems, school performance decline, and quality-of-life impairment in affected children. None of this systemic Th2 overactivation can be reached by a topical treatment. A cream applied to the elbow reduces the inflammation in the dermis and epidermis at the elbow. It does not reduce the quantity of IL-4 and IL-13 circulating from Th2-activated lymph nodes. It does not restore filaggrin production driven by the systemic IL-4 signal. It does not modify the B-cell class switching that produces the IgE that sensitizes mast cells across all skin surfaces. Dupilumab is a monoclonal antibody that binds the IL-4Rα receptor subunit — the subunit shared by both the IL-4 receptor complex (IL-4Rα/γc) and the IL-13 receptor complex (IL-4Rα/IL-13Rα1). By blocking this shared subunit, a single dupilumab injection simultaneously blocks the signaling of both IL-4 and IL-13. This is the molecular reason it works for atopic dermatitis, asthma, chronic sinusitis with nasal polyps, and eosinophilic esophagitis — they all share the IL-4/IL-13 Th2 axis. In the skin, IL-4Rα blockade reverses the cytokine-driven downregulation of filaggrin and other structural proteins, restoring barrier function. It reduces the inflammatory cell infiltrate in the dermis. It reduces IgE class switching. It reduces the IL-31 signal that drives itch. In clinical trials, dupilumab produces 50–75% reduction in EASI score in the majority of pediatric patients, with 30–40% achieving clear or almost clear skin — outcomes that exceed what maximized topical therapy achieves in severe disease. The injection is subcutaneous, not intravenous. For children under 30 kg, the dose is 300 mg every 4 weeks. The injection takes approximately 30 seconds. For the Spanish-speaking parent, the nurse should frame it this way: 'Las cremas actúan en la piel donde las ponemos — reducen la inflamación en ese lugar. Lo que no pueden hacer es cambiar lo que pasa en el sistema inmune de Diego — los mensajes químicos que el sistema inmune está enviando a la piel de todo su cuerpo. Dupilumab es un medicamento que va al sistema inmune directamente. Bloquea dos mensajes específicos — IL-4 e IL-13 — que son los que están diciéndole a la piel de Diego que produzca menos de las proteínas que la mantienen firme e hidratada, y son los que están causando el picor que no lo deja dormir. La inyección va debajo de la piel, no en la vena — tarda menos de un minuto — y se pone una vez al mes. No es que las cremas no funcionen. Es que la enfermedad de Diego está siendo generada desde adentro de una manera que las cremas no pueden alcanzar, sin importar cuántas usemos o con qué frecuencia.'

How do pediatric dermatology nurses explain watchful waiting for molluscum contagiosum to Spanish-speaking parents when lesions are spreading?

The watchful waiting conversation for molluscum contagiosum is one of the most counterintuitive moments in pediatric dermatology because the family's instinct — that spreading visible skin lesions in a child should be identified and treated — is a reasonable general heuristic for medical problems. The nurse must explain why molluscum contagiosum is an exception to this general rule, what the virus actually does and does not do in an immunocompetent child's body, and why the available treatment options produce a risk-benefit calculus that favors observation over intervention in most cases. Molluscum contagiosum is caused by Molluscum contagiosum virus (MCV), a large double-stranded DNA poxvirus that replicates exclusively within the cytoplasm of keratinocytes — the epithelial cells of the epidermis. This site restriction is fundamental to the clinical behavior of molluscum. The virus cannot replicate in fibroblasts, vascular endothelial cells, immune cells, nerve cells, or any cell type other than keratinocytes. It does not enter the bloodstream. It does not travel to lymph nodes, liver, lungs, or any organ. It does not produce viremia. The infection is, by the nature of the virus's biology, permanently confined to the superficial layer of the skin at the sites where it is replicating. A child with 30 molluscum papules on the trunk and arms has a skin infection in the keratinocytes immediately beneath those 30 papules and nowhere else. The dome-shaped pearly papules with central umbilication that characterize molluscum are individual colonies of virus-replicating keratinocytes. The central umbilication is the pore through which keratinocyte debris containing viral particles is shed — the mechanism of both person-to-person transmission (by direct skin contact or fomites) and autoinoculation (the child scratching a lesion and inoculating adjacent skin). New lesions appearing in the weeks following the first presentation represent autoinoculation events, not viral dissemination through the bloodstream or lymphatics. In an immunocompetent child — a child with a normal adaptive immune system — the immune response to MCV eventually clears the infection. The adaptive immune response to molluscum develops more slowly than for many other viral infections because MCV has evolved several immune evasion mechanisms: it produces proteins that inhibit apoptosis signaling in infected keratinocytes (allowing the cells to survive long enough for viral replication to complete), proteins that interfere with interferon signaling, and proteins that suppress NK-cell activation. These mechanisms delay immune recognition and clearance, which is why molluscum persists for months rather than days. But they do not prevent clearance — they only delay it. In immunocompetent children, the published natural history data consistently show spontaneous clearance in 6–18 months without treatment in the majority of cases, with a median time to clearance of approximately 12–13 months. The treatments available for molluscum — cantharidin application by a clinician, curettage with a curette, cryotherapy with liquid nitrogen — all work by physically or chemically destroying the infected keratinocytes to provoke an immune response. They do not target the virus specifically. Cantharidin (a blistering agent extracted from blister beetles) is applied by the clinician to each individual lesion; it causes epidermal cell death and blister formation beneath the treated lesion, which provokes a local inflammatory response that clears the lesion. But cantharidin can also spread to adjacent healthy skin, producing blistering at unintended sites, and leaves areas of post-inflammatory hypopigmentation — temporary but often prolonged lightening of the treated skin — particularly noticeable in children with darker skin tones. Curettage removes the papule physically with a small curette — effective, but requires physical restraint of a young child for each of 30 or more papules, produces bleeding and pain at each site, and leaves small scars at treated locations. Cryotherapy with liquid nitrogen causes pain at application and post-inflammatory changes similar to cantharidin. In a 4-year-old with 30 lesions that are actively spreading, the treatment calculus is: 30 treatment sites, procedural pain at each, risk of blistering at adjacent healthy skin, risk of post-inflammatory hypopigmentation, and a 6–18 month observation alternative that produces the same outcome (clearance) without any of these consequences. The treatment does not change when the child clears — it only changes where the scars and pigmentation changes appear afterward. For the Spanish-speaking parent, the nurse should explain the infection's confinement: 'Las manchitas de Lucas son una infección de las células de la superficie de la piel — solo esas células, solo en esos lugares. El virus no puede ir a ningún otro lugar en el cuerpo. No entra a la sangre, no va a los órganos, no hay infección interna. Lo que está pasando es que las células inmunes de Lucas todavía están aprendiendo a reconocer el virus — este virus en particular es muy bueno evadiendo al sistema inmune al principio. Pero en los próximos meses, el sistema inmune lo va a identificar y lo va a eliminar. Casi todos los niños con sistema inmune sano eliminan estas manchitas solos en 6 a 18 meses. Las opciones de tratamiento — una sustancia que causa ampollas en cada manchita, o raspar cada una con un instrumento — producen dolor, posible cicatriz, y a veces dejan la piel más clara en esas zonas, especialmente en niños con piel más oscura. Al final, la piel de Lucas queda igual limpia, pero sin haber pasado por ese procedimiento. Para la hermana menor: evitar que Lucas rasque las manchitas y que compartan toallas o ropa de baño reduce el riesgo de contagio — pero no lo elimina completamente hasta que las manchitas desaparezcan.'

What is filaggrin and how do pediatric dermatology nurses explain its role in atopic dermatitis to Spanish-speaking families?

Filaggrin is one of the most clinically important concepts in explaining atopic dermatitis to families because it is the mechanistic bridge between the immune system and the skin barrier — it explains why a child with atopic dermatitis has skin that is dry, cracked, and permeable even between flares, and why the disease is not simply 'sensitive skin' that reacts to irritants but a structural and immunological condition with a genetic basis. Filaggrin (filament-aggregating protein) is a structural protein expressed in the granular layer of the epidermis — the layer of keratinocytes just below the outermost stratum corneum. As keratinocytes in the granular layer undergo terminal differentiation and die to form the stratum corneum, they release filaggrin as part of the cornification process. Filaggrin serves two functions in the stratum corneum: it aggregates keratin intermediate filaments into the dense, tightly packed keratin bundle structure that gives the stratum corneum its mechanical integrity, and it is enzymatically degraded into its component amino acids — pyrrolidone carboxylic acid, urocanic acid, and other hygroscopic molecules — that form the 'natural moisturizing factor' of the stratum corneum, the collection of osmotically active molecules that retain water within the stratum corneumtissue and maintain the barrier hydration that prevents transepidermal water loss. A stratum corneum with normal filaggrin expression has a dense, compact structure with adequate natural moisturizing factor — it resists penetration by environmental allergens, irritants, and microorganisms, and it retains water effectively. A stratum corneum with reduced filaggrin expression — whether from loss-of-function FLG gene mutations (present in approximately 20–30% of children with atopic dermatitis) or from cytokine-driven downregulation by IL-4 and IL-13 — has a looser, more permeable microstructure with inadequate natural moisturizing factor. Environmental allergens (house dust mite proteins, pollen proteins, food allergens) can penetrate through this structurally deficient barrier and contact dendritic cells in the epidermis and dermis, driving allergen sensitization. Bacteria — particularly Staphylococcus aureus, which colonizes the skin of 90% of children with atopic dermatitis compared to 20% of healthy controls — penetrate more easily, produce toxins and proteases that further degrade the barrier, and activate keratinocyte TSLP and IL-33 production, which drives further Th2 inflammation. Transepidermal water loss is elevated — the skin cannot retain water without the structural support of filaggrin-derived natural moisturizing factor — producing the chronic dryness and tight, itchy sensation that families describe as their child's baseline skin state between flares. This is why emollients — applied early, applied frequently, applied liberally to a wet skin surface — are not optional adjuncts to atopic dermatitis management but an active therapeutic intervention. Emollients compensate externally for the barrier function that filaggrin normally provides internally. For the Spanish-speaking family, the nurse should explain filaggrin's role without using the word 'filaggrin' unless the family specifically asks: 'La piel tiene una capa protectora que mantiene la hidratación adentro y los irritantes afuera. En los niños con dermatitis atópica, esa capa protectora no funciona igual que en otros niños — tiene pequeñas aperturas microscópicas que dejan salir el agua y entrar los alérgenos y bacterias. Por eso la piel de Valentina se siente seca entre los brotes, y por eso el eczema vuelve: la puerta está siempre un poco abierta. La hidratante no es solo para sentir la piel suave — está reemplazando una función que la capa protectora de la piel de Valentina no puede hacer sola. Por eso aplicarla todos los días, aunque la piel se vea bien, es parte del tratamiento, no solo el cuidado de la piel.'

What are the key Spanish phrases pediatric dermatology nurses use for the three clinic scenarios: tacrolimus introduction, dupilumab recommendation, and molluscum watchful waiting?

Pediatric dermatology clinic nurses working with Spanish-speaking families need clinical Spanish for three distinct communication moments: explaining why tacrolimus replaces a topical steroid that was working on the face and flexures; explaining why a biologic injection is recommended when topical treatments have reached their ceiling in severe atopic dermatitis; and explaining why spreading molluscum contagiosum lesions are observed rather than treated. For tacrolimus introduction — explaining the switch from a working steroid: 'Entiendo que la hidrocortisona le estaba funcionando a Valentina, y la pregunta de por qué cambiarla es completamente lógica. La hidrocortisona funciona suprimiendo la inflamación con mucha potencia — es un esteroide, y los esteroides hacen eso muy bien. El problema no es que deje de funcionar. El problema es que cuando se usa durante mucho tiempo en la cara — donde la piel es la más delgada del cuerpo y absorbe más el medicamento — puede adelgazar la piel y debilitar los vasos pequeños debajo. En la cara de una niña de cinco años, eso es algo que queremos evitar. El tacrolimus no es un esteroide. Funciona de una manera completamente distinta: bloquea solo las células inmunes que causan la inflamación, sin tocar las células que mantienen el grosor y la estructura de la piel. El resultado que vemos en la piel puede ser muy parecido — el enrojecimiento y el picor bajan — pero sin ese riesgo con el uso prolongado.' For addressing the concern that tacrolimus might be weaker: 'En la cara y los pliegues, donde el tacrolimus está aprobado para niños, es tan efectivo como los esteroides de potencia mediana para controlar el eczema. No es un medicamento débil — es un medicamento que funciona de manera diferente y que es el indicado para esas zonas específicamente. Para otras partes del cuerpo donde la piel es más gruesa, podemos seguir usando el esteroide de forma intermitente para los brotes agudos. El tacrolimus es el que usamos de manera continua en la cara y los pliegues.' For dupilumab — explaining what topicals cannot reach: 'Las cremas hacen algo muy importante — controlan la inflamación en el lugar donde las ponemos. Lo que no pueden hacer, sin importar cuál usemos o con qué frecuencia, es cambiar lo que está pasando en el sistema inmune de Diego. Su sistema inmune está enviando señales químicas — dos señales específicas que se llaman IL-4 e IL-13 — que le dicen a la piel de todo su cuerpo que produzca menos de las proteínas que la protegen y que causan el picor que no lo deja dormir. Dupilumab bloquea esas dos señales directamente. No es que las cremas no funcionen — es que la enfermedad de Diego está siendo generada desde un lugar donde las cremas no pueden llegar.' For explaining the injection: 'La inyección va debajo de la piel del muslo o el abdomen — no en la vena. Tarda menos de un minuto. Se pone una vez al mes. Muchos niños la toleran mejor que los procedimientos de las cremas, especialmente cuando la piel está muy irritada. Los primeros días pueden aparecer pequeñas irritaciones en el ojo — es el efecto secundario más común — pero suelen resolverse solos o con gotas lubricantes. Lo que los estudios muestran es que la mayoría de los niños con la severidad de Diego mejoran de manera significativa en las primeras 16 semanas.' For molluscum watchful waiting — explaining why observation is the treatment: 'Sé que ver manchitas que se están extendiendo produce la urgencia de tratarlas. Quiero explicarle por qué en este caso esperar es la decisión médica correcta, no una falta de acción. El virus que causa el molluscum solo puede vivir en las células de la superficie de la piel — no puede ir a ningún otro lugar en el cuerpo de Lucas. No hay infección interna. El sistema inmune de Lucas lo va a eliminar — este virus en particular es muy hábil para esconderse al principio, lo que es la razón por la que tarda meses en resolverse, pero en niños sanos el sistema inmune siempre lo elimina. El tiempo típico es entre 6 y 18 meses.' For addressing the spreading concern: 'Las manchitas nuevas que están apareciendo son por el roce de la piel — Lucas toca una manchita y lleva el virus a la piel de al lado. No es que el virus se esté extendiendo a través de la sangre. Si tratamos cada manchita con el medicamento que usamos para esto — que hace ampollas en la piel — Lucas va a tener dolor en cada manchita que tratemos, y hay riesgo de que la ampolla se extienda un poco a la piel sana del lado. Y cuando la piel sana, puede quedar más clara en esos puntos, especialmente en niños con piel más oscura. Al final, la piel queda limpia de la misma manera que si esperáramos — solo que sin pasar por todo eso. Para reducir que se siga extendiendo: toallas individuales, ropa de baño separada, y tratar de recordarle a Lucas que no rasque.' For sibling protection concerns: 'Para la hermana menor: el molluscum se transmite por contacto directo de piel a piel o por objetos compartidos como toallas y esponjas. Toallas separadas y evitar el contacto directo con las manchitas reduce el riesgo, pero no lo elimina completamente. Si la hermana no lo tiene todavía, hay una posibilidad de que lo desarrolle — y si lo desarrolla, el cuerpo de ella también lo va a eliminar solo en su momento. El molluscum es muy común en niños de esta edad — es molesto y se ve preocupante, pero no causa ningún daño.'

← All posts September 26, 2026

Spanish for pediatric dermatology clinic nurses — the mother who cannot understand why tacrolimus ointment is prescribed instead of hydrocortisone when the steroid was working, the father who cannot understand why a biologic injection is recommended for severe atopic dermatitis when topical creams are available, and the mother who cannot understand why her son’s spreading molluscum contagiosum lesions are being observed rather than treated

Three pediatric dermatology conversations: Valentina Cruz-Fuentes, 5, from Houston, whose mother cannot understand why tacrolimus replaced hydrocortisone on the face and flexures when the steroid was controlling her eczema, not knowing tacrolimus is a calcineurin inhibitor that blocks T-cell activation at the inflamed site without causing the atrophy, telangiectasia, and HPA-axis suppression that topical steroids produce with prolonged use on anatomically vulnerable skin; Diego Herrera-Morales, 11, from San Antonio, whose father cannot understand why a monthly injection is recommended when topical creams are available for atopic dermatitis, not knowing dupilumab blocks the IL-4Rα receptor shared by IL-4 and IL-13 and modifies the systemic Th2 disease mechanism that topical treatments cannot reach regardless of potency or adherence; and Lucas Espinoza-Reyes, 4, from Dallas, whose mother cannot understand why his spreading molluscum contagiosum lesions are not being treated, not knowing MCV is confined to keratinocytes without systemic risk, clears spontaneously in 6–18 months in immunocompetent children, and available treatments cause procedural pain, scarring, and post-inflammatory hypopigmentation that cause more distress than the self-limited infection.

The pediatric dermatology nurse’s communication challenge in the outpatient clinic

Pediatric dermatology is built around conditions that are visible and therefore terrifying to families in a way that internal medicine conditions are not — a spreading rash, a lesion that keeps appearing, skin that looks like it is deteriorating despite treatment. It is also built around treatment decisions that are counterintuitive from the family’s perspective: stopping a medication that is working, starting an injection for a skin condition, watching lesions spread without intervening.

The Spanish-speaking parent in a pediatric dermatology clinic often arrives with three layers of concern. The first is the immediate clinical concern — the child’s skin, the itch that disturbs sleep, the spreading lesion. The second is a gap between their understanding of what they observe and what the medical recommendation is: the steroid works, so why change it; the lesions are spreading, so why wait; the injection sounds extreme for a skin condition. The third is the absence of a mechanistic framework that would make the recommendation make sense from first principles.

A mother who understands why the face is different from the arm in terms of steroid absorption and structural risk will apply tacrolimus consistently rather than reverting to the hydrocortisone that “worked faster.” A father who understands what IL-4 and IL-13 do systemically and why a cream applied to elbow cannot intercept a cytokine circulating from a lymph node will understand why the injection is not an escalation but a targeting of the disease where it actually originates. A mother who understands that molluscum contagiosum virus lives only in keratinocytes and that the immune system reliably clears it in under two years without treatment will not drive to an urgent care demanding cantharidin for thirty lesions in a 4-year-old.

Three conversations from a pediatric dermatology clinic:

Scenario 1: Valentina Cruz-Fuentes — 5 years old, Houston, Texas

Valentina Cruz-Fuentes had had eczema since she was four months old. Her mother Rosa had first noticed the dry, rough patches behind Valentina’s knees and on her cheeks at the two-month visit, but the pediatrician had attributed them to normal newborn skin variation. By four months the patches had become inflamed — erythematous, lichenified from scratching, weeping slightly in the antecubital fossae — and the pediatrician had started hydrocortisone 1% cream twice daily to affected areas, with instructions to apply emollient afterward. Rosa had found a routine: thin application of hydrocortisone to the red areas in the morning, heavy layer of emollient at bedtime. Within three days of each application cycle, the skin calmed. When she stopped the hydrocortisone, the skin flared within a week.

For eighteen months, Rosa had managed Valentina’s eczema with this cycle. The pattern was reliable: hydrocortisone on, flare down; hydrocortisone off, flare returns within days. At the referral visit to pediatric dermatology, the dermatologist had examined Valentina’s face carefully — the periorbital area, the nasolabial folds, the cheeks — and then examined the antecubital and popliteal fossae. She had noted mild hypopigmentation and skin thinning in the periorbital area consistent with prolonged steroid use. She had prescribed tacrolimus 0.03% ointment for the face and flexural areas and asked to see Valentina back in six weeks.

Rosa had picked up the tacrolimus at the pharmacy. She had read the package insert in Spanish three times. She had not filled the second prescription — the hydrocortisone had been in the cabinet for months and had always worked. When she came to the follow-up visit, nurse María Solano-Vega saw immediately from the chart that the tacrolimus had not been started.

“El ungüento de tacrolimus — lo tiene?” María asked, when they were settled in the exam room. Valentina was on the exam table, holding a small paper cup of water with both hands and drinking from it with total concentration. (The tacrolimus ointment — do you have it?)

“Lo tengo en casa,” Rosa said. “No lo he empezado. La hidrocortisona funciona. No entiendo por qué cambiarla.” (I have it at home. I have not started it. The hydrocortisone works. I do not understand why you are changing it.)

María sat down at the counter and turned her chair toward Rosa. “La pregunta tiene mucho sentido, porque la hidrocortisona sí funciona — eso es exactamente el punto de partida. Tiene razón en que funciona. Lo que quiero explicarle es por qué eso no es suficiente para seguir usándola en la cara y los pliegues de Valentina a largo plazo. Necesito unos minutos para explicar la diferencia entre los dos medicamentos.” (The question makes a lot of sense, because hydrocortisone does work — that is exactly the starting point. You are right that it works. What I want to explain to you is why that is not enough reason to keep using it on Valentina’s face and flexures long-term. I need a few minutes to explain the difference between the two medications.)

Rosa straightened in her chair. She had driven forty minutes for this appointment. “Adelante.” (Go ahead.)

“La hidrocortisona es un esteroide. Los esteroides funcionan activando unos receptores en las células de la piel que apagan la inflamación de manera muy rápida y muy potente. Eso es por qué la piel de Valentina mejora en tres días — los esteroides son muy buenos en eso. El problema no es que la hidrocortisona funcione mal. El problema es que esos mismos receptores que apagan la inflamación también afectan a otras células en la piel — específicamente, las células que producen el colágeno que mantiene la piel firme y gruesa. Cuando los esteroides se usan durante mucho tiempo, el colágeno en la dermis — la capa de abajo de la piel — empieza a reducirse.” (Hydrocortisone is a steroid. Steroids work by activating receptors in the skin cells that turn off inflammation very quickly and very powerfully. That is why Valentina’s skin improves in three days — steroids are very good at that. The problem is not that hydrocortisone works poorly. The problem is that those same receptors that turn off inflammation also affect other cells in the skin — specifically, the cells that produce the collagen that keeps the skin firm and thick. When steroids are used for a long time, the collagen in the dermis — the layer below the skin surface — starts to decrease.)

“¿Y eso qué produce?” Rosa asked. (And what does that cause?)

“La piel se adelgaza. Los vasos pequeños debajo se vuelven más frágiles — eso produce esas venitas rojas que se ven con el uso prolongado. Y en la cara, que es donde la piel ya es naturalmente más delgada que en cualquier otra parte del cuerpo, ese proceso ocurre más rápido y con esteroides que en otras partes serían demasiado suaves para preocupar. La dermatóloga vio en la piel de Valentina alrededor de los ojos una ligera aclaración y adelgazamiento que son las primeras señales de eso. En los pliegues — el interior del codo y la parte de atrás de la rodilla — la piel también es más delgada y absorbe más el medicamento que en la espalda o el brazo.” (The skin thins. The small vessels below become more fragile — that produces those small red veins that appear with prolonged use. And on the face, which is where the skin is already naturally thinner than anywhere else on the body, that process happens faster and with steroids that in other places would be too mild to worry about. The dermatologist saw in Valentina’s skin around the eyes a slight lightening and thinning that are the first signs of that. In the flexures — the inner elbow and the back of the knee — the skin is also thinner and absorbs more medication than on the back or the arm.)

Rosa was quiet for a moment. She was looking at Valentina’s face — the periorbital area, which she had treated faithfully every time a flare appeared. “¿Entonces le hice daño?” she asked, her voice quiet. (So I hurt her?)

“No,” María said immediately, directly. “Lo que hizo, lo hizo bien — usó el medicamento que el pediatra le indicó, de la manera que le indicaron, y la piel de Valentina no tuvo infecciones graves ni empeoró de manera peligrosa. Los cambios que vio la dermatóloga son leves y son reversibles. Lo que estamos haciendo ahora es cambiar el medicamento precisamente para que esos cambios se recuperen y no progresen. No hubo un error — el error hubiera sido no notar esos cambios cuando aparecieron.” (No. What you did, you did well — you used the medication the pediatrician prescribed, in the way they prescribed it, and Valentina’s skin had no serious infections and did not worsen dangerously. The changes the dermatologist saw are mild and are reversible. What we are doing now is changing the medication precisely so that those changes recover and do not progress. There was no mistake — the mistake would have been not noticing those changes when they appeared.)

Rosa exhaled. Valentina had finished the water and was holding the empty cup upside down over the exam table, watching it. “¿Y el tacrolimus funciona igual que la hidrocortisona?” (And does tacrolimus work the same way as hydrocortisone?)

“El tacrolimus no es un esteroide — funciona de una manera completamente diferente. Los esteroides apagan todo: la inflamación y también la producción de colágeno. El tacrolimus apaga solo la inflamación — específicamente, bloquea a las células inmunes que están causando el eczema en la piel, sin tocar las células que mantienen la estructura de la piel. No produce adelgazamiento de la piel. No produce las venitas rojas. No hay un límite de cuánto tiempo se puede usar en la cara — es el medicamento que usamos de manera continua precisamente porque no tiene ese riesgo.” (Tacrolimus is not a steroid — it works in a completely different way. Steroids turn off everything: the inflammation and also the collagen production. Tacrolimus turns off only the inflammation — specifically, it blocks the immune cells that are causing the eczema in the skin, without touching the cells that maintain the structure of the skin. It does not produce skin thinning. It does not produce the small red veins. There is no limit on how long it can be used on the face — it is the medication we use continuously precisely because it does not have that risk.)

“¿Y funciona tan rápido como la hidrocortisona?” Rosa asked. (And does it work as fast as hydrocortisone?)

“Los primeros días puede producir una sensación de ardor o calor en la piel — eso es normal y desaparece en la primera semana de uso. Después de eso, la mayoría de los niños ven una mejora similar a la del esteroide en dos a cuatro semanas. No es instantáneo como la hidrocortisona — pero mantiene la mejora sin el precio que los esteroides cobran con el uso prolongado en esas zonas. Para un brote agudo muy intenso en otra parte del cuerpo, podemos aún usar el esteroide de forma corta. Para la cara y los pliegues de Valentina, el tacrolimus es el medicamento de base desde ahora.” (The first few days it can produce a burning or warm sensation in the skin — that is normal and disappears in the first week of use. After that, most children see improvement similar to the steroid in two to four weeks. It is not as instant as hydrocortisone — but it maintains the improvement without the price that steroids charge with prolonged use in those areas. For a very intense acute flare somewhere else on the body, we can still use the steroid for a short course. For Valentina’s face and flexures, tacrolimus is the base medication from now on.)

Rosa nodded slowly. She was looking at the ointment name in her notes. “Bien,” she said. “Lo empiezo esta noche.” (All right. I will start it tonight.)

Scenario 2: Diego Herrera-Morales — 11 years old, San Antonio, Texas

Diego Herrera-Morales had had severe atopic dermatitis since age three. His parents had seen three pediatricians, two allergists, and now a pediatric dermatologist. The management had escalated systematically: emollients, then low-potency steroids, then medium-potency steroids, then tacrolimus 0.1% ointment on the face and neck, then bleach baths twice weekly, then a wet wrap protocol during severe flares. Diego’s EASI score at the current visit was 28 — severe disease — and his IGA was 4. He had missed fourteen days of school in the past six months because of flares that prevented him from sitting comfortably. His sleep was disrupted three to four nights per week by itch.

His father Miguel Herrera had taken the day off work for this visit. He worked in construction management and had learned to read dermatology literature the way he read building specifications — carefully, skeptically, looking for what was left unsaid. He had read the Dupixent website. He had read two clinical trial summaries. He had a question.

“Entiendo que las cremas ya no son suficientes,” Miguel said to nurse Carmen Villanueva-Torres, when the allergist had stepped out of the room to pull up the prior authorization forms. Diego was sitting on the exam table in a paper gown, his arms crossed across his chest, his forearms showing the lichenified, excoriated plaques that had been part of his life for as long as he could remember. “Pero son cremas para la piel. Esto es una inyección, y Diego va a tener once años con una inyección mensual. ¿Por qué no una crema más fuerte?” (I understand that the creams are no longer enough. But these are creams for the skin. This is an injection, and Diego is going to be eleven years old getting a monthly injection. Why not a stronger cream?)

Carmen sat down. Diego looked at his father briefly — the look of a child who has heard a version of this question before and is waiting to hear the answer again. “La pregunta es exactamente la correcta, y la respuesta explica por qué la inyección funciona cuando las cremas no pueden. ¿Me da unos minutos para explicar dónde está la enfermedad de Diego, no solo en la piel sino en el sistema inmune?” (The question is exactly the right one, and the answer explains why the injection works when creams cannot. Will you give me a few minutes to explain where Diego’s disease is — not just in the skin but in the immune system?)

Miguel leaned back. “Adelante.” (Go ahead.)

“Las cremas — los esteroides, el tacrolimus, todas las que Diego ha usado — actúan en la piel donde se ponen. Eso es exactamente su función y lo hacen bien: reducen la inflamación en la zona tratada. El problema es que la dermatitis atópica severa como la de Diego no está siendo generada solo en la piel. Está siendo generada en el sistema inmune, lejos de la piel.” (The creams — the steroids, the tacrolimus, all the ones Diego has used — act on the skin where you put them. That is exactly their function and they do it well: they reduce the inflammation in the treated area. The problem is that severe atopic dermatitis like Diego’s is not being generated only in the skin. It is being generated in the immune system, far from the skin.)

“¿Qué quiere decir eso?” Miguel asked. (What does that mean?)

“El sistema inmune de Diego tiene un grupo de células — los llamamos linfocitos Th2 — que están sobreactivadas. Estas células están en los ganglios linfáticos, en la sangre — no en la piel. Y desde ahí, están produciendo dos mensajes químicos que viajan por el cuerpo hasta llegar a la piel: uno se llama IL-4 y otro se llama IL-13. Cuando estos dos mensajes llegan a la piel, le dicen a las células de la piel que produzcan menos de las proteínas que mantienen la barrera de protección de la piel intacta. Sin esas proteínas, la piel de Diego pierde agua más rápido, se agrieta, y deja entrar bacterias e irritantes con más facilidad — lo que reinicia la inflamación. Al mismo tiempo, IL-4 e IL-13 están causando el picor crónico a través de las terminaciones nerviosas de la piel.” (Diego’s immune system has a group of cells — we call them Th2 lymphocytes — that are overactivated. These cells are in the lymph nodes, in the blood — not in the skin. And from there, they are producing two chemical messages that travel through the body until they reach the skin: one is called IL-4 and the other is called IL-13. When these two messages reach the skin, they tell the skin cells to produce less of the proteins that keep the skin’s protective barrier intact. Without those proteins, Diego’s skin loses water faster, cracks, and lets bacteria and irritants in more easily — which restarts the inflammation. At the same time, IL-4 and IL-13 are causing the chronic itch through the nerve endings in the skin.)

Diego was listening. He was still with his arms crossed, but his posture had shifted slightly — toward attention rather than patience. “¿Y las cremas no llegan ahí?” he asked quietly. (And the creams don’t reach there?)

“No,” Carmen said. “Las cremas llegan a la piel. El IL-4 y el IL-13 vienen desde el sistema inmune, desde la sangre. Una crema puesta en el brazo no puede alcanzar los ganglios linfáticos donde están las células que están produciendo esos mensajes. Es como tratar de apagar un incendio sólo mojando el lugar donde el humo sale — el fuego está en otra parte.” (No. The creams reach the skin. The IL-4 and IL-13 come from the immune system, from the blood. A cream put on the arm cannot reach the lymph nodes where the cells producing those messages are. It is like trying to put out a fire by only wetting the place where the smoke comes out — the fire is somewhere else.)

Miguel was quiet. He was looking at Diego’s arms. “¿Y el dupilumab?” (And dupilumab?)

“El dupilumab es un anticuerpo — una proteína que el cuerpo ya sabe fabricar naturalmente, solo que esta la fabricamos en el laboratorio con una diana específica. Bloquea el receptor que recibe los mensajes de IL-4 e IL-13 — los dos al mismo tiempo, porque ese receptor es compartido. Cuando ese receptor está bloqueado, el mensaje no puede entrar a la célula. La piel deja de recibir la orden de debilitar la barrera. El picor reduce. La inflamación baja. Esto no ocurre solo en la piel donde ponemos una crema — ocurre en toda la piel de Diego al mismo tiempo, porque el medicamento va en la sangre.” (Dupilumab is an antibody — a protein that the body already knows how to make naturally, except this one we make in the laboratory with a specific target. It blocks the receptor that receives the IL-4 and IL-13 messages — both at the same time, because that receptor is shared. When that receptor is blocked, the message cannot enter the cell. The skin stops receiving the instruction to weaken the barrier. The itch decreases. The inflammation goes down. This does not happen only in the skin where we put a cream — it happens in all of Diego’s skin at the same time, because the medication travels in the blood.)

“¿Es una crema más fuerte con otro nombre?” Miguel asked. (Is it a stronger cream with another name?)

“No,” Carmen said. “No es más fuerte. Es diferente. Una crema más fuerte seguiría actuando solo en la piel — no cambiaría nada en el sistema inmune. El dupilumab actúa en el sistema inmune, donde está la raíz de la enfermedad de Diego. Los estudios en niños con la severidad de Diego muestran que el 75 a 80 por ciento mejora de manera significativa en las primeras dieciséis semanas — no sólo en la zona donde aplican crema, sino en toda la piel.” (No. It is not stronger. It is different. A stronger cream would still act only on the skin — it would not change anything in the immune system. Dupilumab acts on the immune system, where the root of Diego’s disease is. Studies in children with Diego’s severity show that 75 to 80 percent improve significantly in the first sixteen weeks — not just in the area where they apply cream, but in all the skin.)

“¿Y la inyección?” (And the injection?)

“Va debajo de la piel del muslo o del abdomen — no en la vena. Es una aguja fina, similar a la que se usa para la insulina. El medicamento no puede ir en pastilla porque las proteínas grandes como los anticuerpos se destruyen en el estómago antes de llegar a la sangre. La inyección dura menos de un minuto. Para Diego, una vez al mes. El efecto secundario más común en niños es una ligera irritación en los ojos en las primeras semanas — la conjuntiva tiene receptores de IL-4 también, y mientras el sistema se ajusta, algunos niños sienten picor en los ojos. Generalmente se resuelve solo o con gotas lubricantes.” (It goes under the skin of the thigh or abdomen — not in the vein. It is a thin needle, similar to the one used for insulin. The medication cannot be in a pill because large proteins like antibodies are destroyed in the stomach before reaching the blood. The injection lasts less than a minute. For Diego, once a month. The most common side effect in children is mild irritation in the eyes in the first few weeks — the conjunctiva also has IL-4 receptors, and while the system adjusts, some children feel itch in the eyes. It usually resolves on its own or with lubricating drops.)

Diego looked at his father. Miguel was looking at Diego’s arms — the arms that had been like this for eight years. He was running the calculation of the past eight years against the calculus of a monthly injection. “Si el fuego está en el sistema inmune y las cremas solo llegan a la piel,” he said slowly, “la crema no va a resolver esto.” (If the fire is in the immune system and the creams only reach the skin, the cream is not going to resolve this.)

“Exactamente,” Carmen said. (Exactly.)

Miguel looked at Diego. Diego was still for a moment — the stillness of a child who has had a bad thing named clearly and found the clarity a relief. “¿Una al mes?” he asked. (One a month?)

“Una al mes,” Carmen confirmed. (One a month.)

Scenario 3: Lucas Espinoza-Reyes — 4 years old, Dallas, Texas

Lucas Espinoza-Reyes had arrived at the pediatric dermatology clinic with his mother Patricia after a six-week escalation that had proceeded through three separate medical encounters: a pediatrician visit at week two where molluscum contagiosum was diagnosed and “watchful waiting” was recommended; a second pediatrician visit at week four when Patricia had returned because new lesions had appeared and she was convinced the infection was progressing; and a telephone consult with a nurse line at week six when Patricia had counted thirty-two lesions and the nurse had referred her to dermatology.

Lucas sat on the exam table eating crackers from a small plastic bag with the methodical patience of a four-year-old who has learned that medical appointments involve waiting and that crackers make waiting better. His trunk and proximal arms showed the characteristic lesions: pearly, dome-shaped papules with central umbilication, ranging from 2 to 5 mm, distributed in a pattern consistent with autoinoculation along scratch lines. Six new lesions were visible that had not been present at the prior pediatrician photographs. Patricia had photographed every visit.

“Se están extendiendo,” Patricia said to nurse Ana Delgado-Herrera, before Ana had a chance to speak. “Cada semana hay más. Le dije al pediatra, y me dijo que esperara. Ahora hay treinta y dos. ¿Cuándo las tratan?” (They are spreading. Every week there are more. I told the pediatrician, and she told me to wait. Now there are thirty-two. When are they going to treat them?)

Ana sat down. She had had this conversation, in some form, several times a week. The number varied — sometimes fifteen lesions, sometimes forty — but the sentence was always the same: when are they going to treat them. “Quiero explicarle exactamente lo que está pasando en la piel de Lucas — no solo que se llama molluscum, sino cómo funciona este virus y por qué la decisión médica correcta en este momento es observar. La respuesta tiene que ver con qué hace el virus en el cuerpo y con qué hacen los tratamientos disponibles. ¿Puedo explicarlo?” (I want to explain to you exactly what is happening in Lucas’s skin — not just that it is called molluscum, but how this virus works and why the correct medical decision right now is to observe. The answer has to do with what the virus does in the body and what the available treatments do. Can I explain?)

Patricia crossed her arms but did not object. Lucas ate another cracker. (Patricia crossed her arms but did not object. Lucas ate another cracker.)

“El virus del molluscum — se llama MCV — sólo puede vivir en un tipo de célula: las células de la superficie de la piel. No puede ir a ningún otro lugar en el cuerpo. No puede entrar a la sangre, no puede llegar al hígado, a los pulmones, a los ganglios linfáticos. No existe infección interna. Cada manchita que ve en la piel de Lucas es un pequeño grupo de células de piel que tienen el virus — solo esas células, solo en ese punto. El resto del cuerpo de Lucas está completamente sano.” (The molluscum virus — called MCV — can only live in one type of cell: the surface cells of the skin. It cannot go anywhere else in the body. It cannot enter the blood, it cannot reach the liver, the lungs, the lymph nodes. There is no internal infection. Every lesion you see on Lucas’s skin is a small cluster of skin cells that have the virus — only those cells, only in that spot. The rest of Lucas’s body is completely healthy.)

“Pero se están extendiendo,” Patricia said. (But they are spreading.)

“Sí, y quiero explicar exactamente por qué — porque la razón importa para entender por qué no es peligroso. Las manchitas nuevas aparecen porque Lucas toca una mancha que ya tiene el virus, y después toca la piel de al lado con los mismos dedos. Así es como el virus llega a un punto nuevo — no por la sangre, no por el sistema linfático. Literalmente por los dedos de Lucas tocando su propia piel. Por eso las manchitas aparecen en patrones — siguiendo las líneas donde rasca. No es que el virus se esté extendiendo por el cuerpo adentro. Se está copiando en la superficie, de punto en punto.” (Yes, and I want to explain exactly why — because the reason matters for understanding why it is not dangerous. The new lesions appear because Lucas touches a lesion that already has the virus, and then touches the skin nearby with the same fingers. That is how the virus reaches a new spot — not through the blood, not through the lymphatic system. Literally through Lucas’s fingers touching his own skin. That is why the lesions appear in patterns — following the lines where he scratches. The virus is not spreading through the body on the inside. It is copying itself on the surface, from spot to spot.)

Patricia was listening. Lucas had run out of crackers and was examining the empty bag with philosophical acceptance. “¿Y el sistema inmune de Lucas?” she asked. (And Lucas’s immune system?)

“El sistema inmune de Lucas está reconociendo el virus — solo que este virus en particular es muy habilidoso para evitar que el sistema inmune lo encuentre rápidamente al principio. Produce proteínas que hacen que las células infectadas de la piel no manden la señal de alarma de la manera habitual. Eso es por qué el molluscum dura meses en vez de días. Pero el sistema inmune de Lucas siempre lo va a encontrar. En niños con sistema inmune sano — como Lucas — todos los estudios muestran que el molluscum desaparece solo, sin tratamiento, en un período de 6 a 18 meses. La mayoría se resuelve en 12 a 13 meses. Sin dejar ninguna marca permanente.” (Lucas’s immune system is recognizing the virus — it is just that this particular virus is very skilled at preventing the immune system from finding it quickly at first. It produces proteins that make the infected skin cells not send the alarm signal in the usual way. That is why molluscum lasts months instead of days. But Lucas’s immune system will always find it eventually. In children with a healthy immune system — like Lucas — all studies show that molluscum disappears on its own, without treatment, in a period of 6 to 18 months. Most resolve in 12 to 13 months. Without leaving any permanent mark.)

“¿Y el tratamiento?” Patricia said. “¿Por qué no tratarlas y ya?” (And the treatment? Why not just treat them and be done with it?)

“Le voy a decir exactamente qué hace cada tratamiento, para que pueda decidir si tiene sentido para Lucas. El tratamiento más común que usamos se llama cantaridina — es un líquido que el médico aplica encima de cada manchita. Lo que hace es destruir las células de la piel en ese punto, causando una ampolla pequeña que eventualmente cae y deja la piel limpia. Funciona. Pero hay tres cosas importantes que saber: primero, puede causar dolor e irritación en cada punto donde se aplica. Segundo, la cantaridina a veces se extiende un poco a la piel sana del lado — lo que produce ampollas en piel que no tenía el virus. Tercero, cuando la piel sana después del tratamiento, puede quedar más clara en esos puntos — lo que llamamos hipopigmentación postinflamatoria. Eso es temporal, pero puede durar meses, especialmente en niños con piel más oscura.” (I am going to tell you exactly what each treatment does, so you can decide if it makes sense for Lucas. The most common treatment we use is called cantharidin — it is a liquid that the doctor applies on top of each lesion. What it does is destroy the skin cells in that spot, causing a small blister that eventually falls off and leaves the skin clean. It works. But there are three important things to know: first, it can cause pain and irritation at each point where it is applied. Second, cantharidin sometimes spreads a little to the healthy skin nearby — which produces blisters in skin that did not have the virus. Third, when the skin heals after treatment, it can be lighter in those spots — what we call post-inflammatory hypopigmentation. That is temporary, but it can last months, especially in children with darker skin tones.)

Patricia was quiet. Lucas had started counting the polka dots on Ana’s lanyard. “¿Y si no trato las treinta y dos manchitas?” she asked. (And if I don’t treat the thirty-two lesions?)

“En un año — quizás dos — la piel de Lucas va a estar igual de limpia. Sin ampollas, sin puntos más claros, sin dolor. El sistema inmune va a hacer el trabajo. La razón por la que el tratamiento existe es principalmente para casos donde hay razones específicas para acortar el tiempo: cuando las manchitas están en un lugar que interfiere con la ropa o el deporte de manera muy significativa, cuando hay compromisos del sistema inmune, o cuando la familia tiene una razón específica para no poder esperar. Para un niño de cuatro años con treinta manchitas en el tronco y los brazos, sin ninguna de esas razones, la observación es la decisión médica correcta.” (In a year — maybe two — Lucas’s skin will be just as clean. No blisters, no lighter spots, no pain. The immune system will do the work. The reason the treatment exists is mainly for cases where there are specific reasons to shorten the timeline: when the lesions are in a place that interferes significantly with clothing or sports, when there are immune system issues, or when the family has a specific reason why they cannot wait. For a four-year-old with thirty lesions on the trunk and arms, without any of those reasons, observation is the correct medical decision.)

“¿Y la hermana menor?” Patricia asked. (And the younger sister?)

“El molluscum se transmite por contacto directo de piel a piel, o por toallas y esponjas compartidas. Toallas separadas, esponja de baño separada, y evitar que Lucas rasque las manchitas y luego toque a la hermana reduce el riesgo. No lo elimina completamente mientras Lucas tiene las manchitas — así que hay posibilidad de que la hermana lo desarrolle. Si eso pasa, el cuerpo de ella también lo va a eliminar solo. El molluscum en niños es muy común — la mayoría de los niños en edad preescolar y escolar lo desarrollan en algún momento. Es muy molesto visualmente, pero no tiene nada que ver con la salud interna de Lucas ni de su hermana.” (Molluscum is transmitted by direct skin-to-skin contact, or through shared towels and washcloths. Separate towels, separate bath sponge, and preventing Lucas from scratching the lesions and then touching his sister reduces the risk. It does not eliminate it completely while Lucas has the lesions — so there is a possibility that his sister will develop it. If that happens, her body will also clear it on its own. Molluscum in children is very common — the majority of preschool and school-age children develop it at some point. It is very bothersome visually, but it has nothing to do with Lucas’s or his sister’s internal health.)

Patricia looked at Lucas, who had moved on from the lanyard and was now studying the anatomy poster on the wall with the fascinated incomprehension of a four-year-old confronted with a labeled cross-section of a lung. She looked at his arms. The lesions were there, pearly and numerous, doing nothing except existing. “Entonces esperar es el tratamiento,” she said. (So waiting is the treatment.)

“Sí,” Ana said. “El sistema inmune de Lucas es el tratamiento. Nosotros lo que hacemos es confirmar que está sano, que no hay ninguna razón específica para intervenir, y darle a usted la información para manejar esto en casa sin que sea una emergencia cada semana. Le voy a dar por escrito la lista de lo que buscar — si Lucas tuviera una infección bacteriana encima de alguna manchita, eso sí lo tratamos. Pero las manchitas del molluscum en sí mismas: el tiempo las resuelve.” (Yes. Lucas’s immune system is the treatment. What we do is confirm that he is healthy, that there is no specific reason to intervene, and give you the information to manage this at home without it being an emergency every week. I am going to give you in writing the list of things to watch for — if Lucas were to get a bacterial infection on top of one of the lesions, we would treat that. But the molluscum lesions themselves: time resolves them.)

Eight practical phrases for pediatric dermatology clinic nurses

Tacrolimus on the face is not a downgrade from hydrocortisone — it is a different drug class for a different anatomical risk. Topical corticosteroids activate glucocorticoid receptors in fibroblasts as well as immune cells, suppressing collagen synthesis in the dermis. Facial skin is the thinnest in the body with the highest percutaneous absorption rate; prolonged steroid use produces skin atrophy, telangiectasia, and perioral dermatitis at doses and durations that cause no visible harm on the back or limbs. Tacrolimus blocks calcineurin in T cells only — no glucocorticoid receptor activation, no fibroblast suppression, no collagen synthesis impairment regardless of duration or site.
The HPA-axis suppression concern with topical steroids is real in children with AD. Children have thinner skin and higher body-surface-area-to-weight ratios than adults; percutaneous corticosteroid absorption is higher. Children with atopic dermatitis have chronically disrupted skin barriers that further increase absorption. Prolonged application of even hydrocortisone 1% to large inflamed surface areas in young children can produce measurable cortisol suppression on stimulation testing. Tacrolimus does not suppress cortisol production at any dose or duration.
Severe atopic dermatitis is a systemic Th2 dysregulation, not a skin-only condition. IL-4 and IL-13, produced by overactivated Th2 lymphocytes in the blood and lymphoid tissue, circulate systemically and act on keratinocytes via IL-4Rα receptor complexes to downregulate filaggrin, loricrin, and involucrin production — the structural proteins of the stratum corneum. This systemic signal drives barrier dysfunction throughout the skin surface and cannot be intercepted by a topical treatment applied to individual patches.
Dupilumab blocks both IL-4 and IL-13 with a single injection. IL-4Rα is the shared subunit of both the IL-4 receptor (IL-4Rα/γc) and the IL-13 receptor (IL-4Rα/IL-13Rα1). Blocking IL-4Rα simultaneously eliminates both cytokine signals. This is why dupilumab improves atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis — all Th2-IL-4/IL-13 axis diseases — with a single mechanism.
Dupilumab must be injected because it is a protein that cannot survive oral administration. Monoclonal antibodies are large molecular-weight proteins that are cleaved by gastric and intestinal proteases before they can be absorbed intact. Subcutaneous injection delivers the intact antibody to the lymphatic system and bloodstream, where it circulates and binds IL-4Rα throughout the body. There is no oral equivalent for monoclonal antibody biologics with this molecular size.
Molluscum contagiosum virus is biologically confined to keratinocytes. MCV has no tropism for any cell type other than differentiated keratinocytes. It cannot replicate in fibroblasts, vascular endothelial cells, lymphocytes, hepatocytes, or any other cell. It does not produce viremia. An immunocompetent child with 50 molluscum lesions has MCV replicating in the keratinocytes immediately beneath those 50 papules and nowhere else in the body.
Autoinoculation explains lesion spread — not internal viral dissemination. The central umbilication of each molluscum papule is the exit pore for keratinocyte debris containing virions. When a child scratches a papule and touches adjacent skin, virions are mechanically inoculated onto the new site. New lesions appearing in linear patterns following scratch lines are autoinoculation events. The virus does not travel through the bloodstream or lymphatics to new sites.
Cantharidin, curettage, and cryotherapy produce outcomes that must be weighed against a 6–18 month spontaneous clearance baseline. All three treatments cause the immune system to clear the treated site via induced inflammation — they do not target MCV specifically. Cantharidin produces blistering at treated sites with risk of spread to adjacent healthy skin; post-inflammatory hypopigmentation is a common sequela, particularly in children with Fitzpatrick skin types III–VI. Curettage requires physical restraint in young children and produces point bleeding and minor scarring at each treated site. Cryotherapy produces pain at application and similar post-inflammatory changes. In a 4-year-old with 30 lesions and no immune compromise, these risk-benefit profiles favor observation in most clinical contexts.

The specialty’s communication pattern

Pediatric dermatology clinic nurses working with Spanish-speaking families encounter three structural communication failures that recur across diagnoses. The first is the substitution failure: a treatment that was working is replaced by something new, and the family interprets the replacement as evidence that either the original treatment was wrong or the new one is inferior. Rosa’s response to tacrolimus is this failure — hydrocortisone worked, so why change it. The correct frame is not “the steroid was wrong” but “the steroid was right for short-term control, and tacrolimus is right for long-term maintenance in anatomically vulnerable areas.” The distinction requires explaining that the two drugs work through different mechanisms and are appropriate at different time scales and anatomical contexts — not that one is better than the other in absolute terms.

The second is the escalation failure: a systemic treatment is recommended for a condition the family understands as local, and the escalation reads as severity rather than mechanism. Miguel’s response to dupilumab is this failure — the condition is on Diego’s skin, the injection goes into the body, and the escalation in route signals escalation in severity. The correct frame requires moving the family’s mental model of the disease from “skin condition” to “systemic immune dysregulation that manifests in the skin.” Once that move is made, an injection that reaches the immune system makes more sense than a cream that cannot. The key phrase is not “the cream is not strong enough” — it is “the cream cannot reach where the disease is generated.”

The third is the inaction failure: a spreading, visible clinical finding is being observed rather than treated, and observation reads as negligence or pessimism. Patricia’s response to watchful waiting for molluscum is this failure — visible lesions are spreading, the doctor says wait, and the inference is that the doctor is either not concerned enough or has given up. The correct frame requires convincing the family that the immune system is already the treatment — that the question is not whether Lucas will clear but when, and that the available alternatives produce harm without shortening the time to the same outcome. The key phrase is not “we can’t do anything” — it is “the thing that clears this is already working inside Lucas; what we are deciding is whether to add a procedure that causes pain and pigmentation changes without changing the endpoint.”

All three failures share a structure: the family’s prior knowledge provides a heuristic (“if the treatment works, keep using it”; “a skin condition needs a skin treatment”; “visible spreading needs intervention”) that is generally correct and that leads to the wrong conclusion in this specific clinical context. The nurse’s task is not to dismiss the heuristic but to provide the additional mechanistic information that makes this case the exception. A family that understands the exception does not need to be told what to do — they arrive at the recommendation themselves.

For more clinical-Spanish resources for pediatric and specialty nurses, see Spanish for dermatology clinic nurses, Spanish for pediatric allergy and immunology clinic nurses, Spanish for pediatric nurses, Spanish for pediatric emergency nurses, and Spanish for infectious disease clinic nurses. The free practice scenarios and the 50 Spanish phrases PDF are available without login.